POC (point-of-care) bladder cancer test proves accurate:
This article was originally published in Clinica
Executive Summary
Matritech's point-of-care (POC) test for bladder cancer is as accurate as the company's FDA-approved laboratory-based version of the test, according to a study of 96 individuals. The overall concordance between the POC NMP22 BladderChek test and Matritech's current NMP22 microplate format test was 95%, reports the Newton, Massachusetts firm. BladderChek works much like a home pregnancy test and can produce results while the patient is in the doctor's office. Current tests performed in a central laboratory take two to three days to deliver results, said the company.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.